ClinicalTrials.gg
Not yet recruitingNCT07948044MASA-AFUpdated Nov 19, 2026

Prospective Validation of the MASA Score for Detection of Previously Unknown Atrial Fibrillation

An observational study in Atrial Fibrillation (AF), Ischemic Stroke and Hemorrhagic Stroke, sponsored by Special Hospital for Cerebrovascular Diseases "Sveti Sava". Not yet recruiting at 1 site in Serbia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Special Hospital for Cerebrovascular Diseases "Sveti Sava" · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies in Atrial Fibrillation with a site in Serbia — 5 open to participants now, 7 under way, 2 of them phase 3. Atrial Fibrillation · Serbia.

Started
2026
the only one that year
Observational
3 of 18
1 open now
Registered
18th of 18
by date

Among the 18 studies in Atrial Fibrillation with a site in Serbia, this one is the only one that started in 2026, is one of 3 observational ones, and was the 18th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

5 of the 18 studies in Atrial Fibrillation with a site in Serbia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Serbia have not opened yet or have stopped. Only those recruiting at a site in Serbia →

Who these studies take

Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Atrial Fibrillation with a site in Serbia, or all of them as a file.
02

Study summary

The MASA (Metabolic-Atrial-Septal-Assessment) score is a simple 0-8 point score built from five routinely available variables: estimated glomerular filtration rate, serum triglycerides, absence of atrial septal aneurysm, left atrial diameter, and TAPSE. In a retrospective development cohort (n=246), a score of 5 or more identified patients with atrial fibrillation (AF). This prospective study will test, in consecutive patients with cardiovascular disease or stroke without known AF admitted to the Intensive Care Unit, whether a MASA score of 5 or more identifies those in whom AF is detected by continuous ECG monitoring. The score, its threshold, and the primary outcome are fixed before enrollment and will not be changed.

Read the detailed description

Background: Undetected paroxysmal atrial fibrillation (AF) is a major preventable cause of stroke. Extended ECG monitoring is effective but resource-intensive; a simple score could help select patients who need it most.

Study phases: The study was approved by the Ethics Committee of the Special Hospital for Cerebrovascular Diseases "Sveti Sava" (No. 03/4310, 30 October 2026) under the title "Development of the MASA score for assessing the probability of atrial fibrillation in a retrospective cohort of cardiology patients and its prospective validation in the intensive care unit: a single-center study." Phase 1 (retrospective score development, n=246) is completed. This registration covers Phase 2, the prospective validation in consecutive patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke, or transient ischemic attack) admitted to the Intensive Care Unit.

Pre-specified score (locked before enrollment): eGFR \<60 mL/min/1.73 m² (CKD-EPI 2021) = 1 point; triglycerides \<=1.2 mmol/L = 1 point; atrial septal aneurysm ABSENT on echocardiography = 3 points; left atrial diameter >=46 mm = 1 point; TAPSE \<=17 mm = 2 points. Score range 0-8. Positive screen = score >=5.

Procedures: Consecutive eligible patients undergo blood sampling (serum creatinine, triglycerides) and transthoracic echocardiography (left atrial diameter, TAPSE, interatrial septum assessment) shortly after ICU admission, with heart rhythm recorded at the time of echocardiography. The MASA score is calculated by an investigator not involved in rhythm assessment. All patients, regardless of score, undergo continuous ECG monitoring during the ICU stay. ECG recordings are assessed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader. AF is defined as an episode of at least 30 seconds.

Sample size: At least 61 patients with confirmed AF are required for a precise estimate of sensitivity (target 100). Enrollment continues until at least 61 (target 100) patients with confirmed AF have been enrolled; the anticipated total enrollment is approximately 700 patients, assuming a 10% AF detection rate.

Analysis: Primary-sensitivity and specificity of MASA >=5 with 95% confidence intervals. Secondary-positive and negative predictive values, area under the ROC curve, comparison with age and CHA2DS2-VASc (DeLong test), decision curve analysis, and number of patients monitored per detected AF. Pre-specified sensitivity analysis: serum creatinine >=90 umol/L instead of eGFR. Reporting will follow STARD 2015 and TRIPOD+AI 2024.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Ischemic Stroke
  • Hemorrhagic Stroke

Keywords

  • atrial fibrillation screening
  • risk score
  • atrial septal aneurysm
  • TAPSE
  • left atrial diameter
  • eGFR
  • triglycerides
  • continuous ECG monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adult patients with cardiovascular disease or stroke, without previously documented atrial fibrillation, admitted to the Intensive Care Unit of the Special Hospital for Cerebrovascular Diseases "Sveti Sava", Belgrade, Serbia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Consecutive admission to the Intensive Care Unit with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or )
  • Sinus rhythm on the admission 12-lead
  • Transthoracic echocardiography and blood tests (serum creatinine, triglycerides) feasible shortly after admission

Exclusion criteria

Exclusion Criteria:

  • Any previously documented atrial fibrillation or atrial flutter
  • Atrial fibrillation or atrial flutter on the admission
  • Permanent pacemaker or implantable cardioverter-defibrillator
  • Mechanical mitral valve prosthesis or moderate-to-severe mitral stenosis
  • Inadequate echocardiographic window for measurement of left atrial diameter, TAPSE or assessment of the interatrial septum
  • Expected duration of continuous ECG monitoring shorter than 24 hours
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • ICU patients with cardiovascular disease or stroke without known AF

    Consecutive adult patients with cardiovascular disease or stroke (ischemic stroke, hemorrhagic stroke or transient ischemic attack), without previously documented atrial fibrillation, admitted to the Intensive Care Unit. All participants have the MASA score calculated and undergo continuous ECG monitoring during the ICU stay.

    Diagnostic Test: MASA score

Interventions

  • Diagnostic testMASA score

    Calculation of the MASA score (range 0-8) from routinely collected data: eGFR \<60 mL/min/1.73 m2 = 1 point; triglycerides \<=1.2 mmol/L = 1 point; atrial septal aneurysm absent on echocardiography = 3 points; left atrial diameter \>=46 mm = 1 point; TAPSE \<=17 mm = 2 points. A score \>=5 is considered a positive screen. The score does not influence patient management; all patients undergo continuous ECG monitoring regardless of score.

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity of MASA Score >=5 for Detection of Atrial Fibrillation

    Sensitivity and specificity (with 95% confidence intervals) of a MASA score \>=5 for atrial fibrillation detected by continuous ECG monitoring. Atrial fibrillation is defined as an episode lasting at least 30 seconds, confirmed by two readers blinded to the MASA score and its components; disagreements are resolved by a third reader.

    Time frame: From ICU admission to ICU discharge (up to 30 days)

Secondary outcomes

  1. Positive and Negative Predictive Values of MASA Score >=5

    Positive and negative predictive values (with 95% confidence intervals) of a MASA score \>=5 for atrial fibrillation detected by continuous ECG monitoring.

    Time frame: From ICU admission to ICU discharge (up to 30 days)

  2. Discriminative Performance of the MASA Score

    Area under the ROC curve (with 95% confidence interval) of the MASA score for atrial fibrillation, compared with age and CHA2DS2-VASc score using the DeLong test.

    Time frame: From ICU admission to ICU discharge (up to 30 days)

  3. Clinical Net Benefit of MASA-Guided Monitoring

    Net benefit of selecting patients for extended ECG monitoring by MASA score \>=5, assessed by decision curve analysis.

    Time frame: From ICU admission to ICU discharge (up to 30 days)

  4. Number of Patients Monitored per Detected Atrial Fibrillation

    Number of patients who would need extended ECG monitoring to detect one case of atrial fibrillation when monitoring is restricted to patients with MASA score \>=5.

    Time frame: From ICU admission to ICU discharge (up to 30 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results, together with the analysis code, will be made available.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: After publication of the primary results, for at least 5 years.

Access criteria: Available to qualified researchers on reasonable request to the principal investigator, for non-commercial research purposes.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 24 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948044
Lead sponsor
Special Hospital for Cerebrovascular Diseases "Sveti Sava"
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Dejan Munjiza, MD, MSc
Contact
munjizad@gmail.com
+381608018437
Dejan Munjiza, MD, MSc
principal investigator · Special Hospital for Cerebrovascular Diseases "Sveti Sava"

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion